NDC 70860-216-41 - Busulfan
This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.
- Product NDC
- 70860-216
- Requested NDC
- 70860-216-41
- Package NDCs from labels
- 70860-216-41, 70860-216-10
- Manufacturer
- Athenex Pharmaceutical Division, LLC.
- Effective date
- 2021-05-03
- Current FDA listing
- Not matched in FDA.report NDC product tables
DailyMed Labels#
| Label | Manufacturer | Effective date | Type |
|---|---|---|---|
| Busulfan - Athenex Pharmaceutical Division, LLC. | Athenex Pharmaceutical Division, LLC. | 2021-05-03 | HUMAN PRESCRIPTION DRUG LABEL |
DailyMed Billing Units#
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 70860-216-10 | ML - Milliliter | 70860-216 | b6e12cdb-240b-4e3e-9391-88e8bdf927ee | 1 | 2019-04-11 |
| 70860-216-41 | ML - Milliliter | 70860-216 | 49a3669f-ba7e-422c-908d-7d164ada4980 | 1 | 2019-04-11 |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Busulfan | BUSULFAN | Sagent Pharmaceuticals | 086a715e-4958-4bb5-9ebd-86171e6b6203 | 2026-07-29 | Boxed warning, Warnings, Adverse reactions | G1LN9045DK |
| MYLERAN | BUSULFAN | Waylis Therapeutics LLC | 2da33e5b-dcfb-4cdf-b163-50398e42f41c | 2025-01-08 | Boxed warning, Warnings, Adverse reactions | G1LN9045DK |
| Busulfan | BUSULFAN | Eugia US LLC | 06883ac0-4b2a-4f26-89bf-512d37b9ba7f | 2024-06-27 | Boxed warning, Warnings, Adverse reactions | G1LN9045DK |
| Busulfan | BUSULFAN | Accord Healthcare, Inc | fe0ddd44-ef02-4827-b164-7fcbb45bcc1b | 2024-01-05 | Boxed warning, Warnings, Adverse reactions | G1LN9045DK |
| Busulfan | BUSULFAN | Pharmascience Inc. | d0fe44f9-7747-4909-b927-3b24aa6e7e09 | 2022-05-18 | Boxed warning, Warnings, Adverse reactions | G1LN9045DK |
| BUSULFAN | BUSULFAN | Hospira, Inc. | b9c7f0dc-988d-466e-8031-400ec4f60f21 | 2021-08-09 | Boxed warning, Warnings, Adverse reactions | G1LN9045DK |
| Busulfan | BUSULFAN | Meitheal Pharmaceuticals Inc. | dc384f16-4e25-458e-874c-553f81c6d8c9 | 2021-06-14 | Boxed warning, Warnings, Adverse reactions | G1LN9045DK |
| Busulfan | BUSULFAN | Meitheal Pharmaceuticals Inc. | 6e68ab21-19bd-4b7e-b8d0-bf284d5af183 | 2021-06-14 | Boxed warning, Warnings, Adverse reactions | G1LN9045DK |
| 8189e34d-4b3d-4a39-a42f-870cfd05baaf | 5eb97384-3dc0-4172-9ffc-693be91077dc | 2021-05-03 | Boxed warning, Warnings, Adverse reactions | 8189e34d-4b3d-4a39-a42f-870cfd05baaf 5eb97384-3dc0-4172-9ffc-693be91077dc | ||
| Busulfan | BUSULFAN | Amneal Pharmaceuticals LLC | ac9448da-37ad-4609-9aef-eedf8be0f69c | 2020-09-23 | Boxed warning, Warnings, Adverse reactions | G1LN9045DK |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.